Protokol; provádění Studie Sample Clauses

Protokol; provádění Studie. (a) Institution and Investigator (defined below) will conduct the clinical study (“Study“) in relation to the Xxxxxx product (s) …….. (the “Study Product(s)”) pursuant to the terms of this Statement of Work and the Master Agreement and in strict adherence to Protocol No entitled “ ………. ” (the “Protocol”), as the same may be amended from time to time in writing by Xxxxxx, and any other written instruction that may be provided in case they are needed to Institution by Xxxxxx. Investigator hereby acknowledges reviewing and understanding the Protocol, as evidenced by the Investigator’s signature on the Investigator Agreement (s) contained within the Protocol, as may be amended from time to time, all of which are incorporated herein by reference. (a) Zdravotnické zařízení a Zkoušející (definován níže) provedou klinickou studii (xxxx xxx „Studie“) v souvislosti s Hodnoceným produktem či produkty společnosti Abbott ………. (xxxx xxx “Hodnocený produkt nebo Hodnocené produkty“) v souladu s podmínkami této Dílčí smlouvy a Rámcovou smlouvou, a budou přísně dodržovat Protokol č. ………. nazvaný „………. “ (xxxx xxx „Protokol“), jenž může společnosti Abbott čas od času písemnou formou změnit, a také veškeré další písemné pokyny, které společnost Xxxxxx může Zdravotnickému zařízení v případech potřeby poskytnout. Zkoušející tímto potvrzuje, že si prostudoval Protokol a porozuměl mu, o čemž svědčí jeho podpis na Smlouvě pro Zkoušejícího, která je obsažena v Protokolu, a je srozuměn s xxx, že Protokol může být čas od času změněn, přičemž všechny takové dodatky jsou zde začleněny odkazem.
AutoNDA by SimpleDocs
Protokol; provádění Studie. (a) The Institution and Investigator shall conduct the Study in accordance with (i) the Protocol, as amended from time to time, (ii) the established timetable for the Study, and (iii) any additional written instructions reasonably provided by ImmunoGen or its agents to the Institution or the Investigator arising during the course of the Study which could not have been anticipated at the outset. Institution or Investigator may deviate from the Protocol without the consent of ImmunoGen only in emergency circumstances where required to protect the safety, health, or rights of a Study Subject. ImmunoGen shall be informed immediately of any such Protocol deviation. Furthermore, the Institution and Investigator shall not alter or amend, or permit any Personnel (as defined below) to alter or amend, the Protocol in any way without the prior written consent of ImmunoGen, unless required by law to protect the safety, health, or rights of the Study Subjects, in which case ImmunoGen shall be informed immediately of any such Protocol alteration or amendment. (a) Zdravotnické zařízení a Zkoušející budou provádět Studii v souladu (i) s Protokolem a jeho případnými budoucími dodatky, (ii) se stanoveným harmonogramem Studie a (iii) s veškerými dalšími písemnými pokyny odůvodněně vydanými společností ImmunoGen nebo jejími zástupci Zdravotnickému zařízení nebo Zkoušejícímu, které vzniknou v průběhu Studie a které nebylo možné předvídat na jeho počátku. Zdravotnické zařízení nebo Zkoušející se mohou od Protokolu odchýlit bez souhlasu společnosti ImmunoGen pouze za naléhavých okolností, kdy je nutné chránit bezpečnost, zdraví nebo práva Subjektu studie. Společnost ImmunoGen musí být o jakékoli takové odchylce od Protokolu neprodleně informována. Zdravotnické zařízení a Zkoušející xxxx nebudou měnit ani upravovat, ani nedovolí kterémukoli členu Personálu (definovanému níže) jakkoli měnit či upravovat Protokol bez předchozího písemného souhlasu společnosti ImmunoGen, pokud to není vyžadováno ze zákona k ochraně bezpečnosti, zdraví nebo práv Subjektů studie; v takovém případě musí být společnost ImmunoGen o jakékoli takové změně či úpravě Protokolu neprodleně informována.

Related to Protokol; provádění Studie

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Protocol No action to coerce or censor or penalize any negotiation participant shall be made or implied by any other member as a result of participation in the negotiation process.

  • COVID-19 Protocols Contractor will abide by all applicable COVID-19 protocols set forth in the District’s Reopening and COVID-19 Mitigation Plan and the safety guidelines for COVID-19 prevention established by the California Department of Public Health and the Ventura County Department of Public Health.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Trials The Ship shall run the following test and trials:

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!